Haemonetics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Haemonetics (HAE).

Price Target Range — 13 Quarters

Analyst Consensus — 11 Analysts

1S.Buy

8Buy

2Hold

Consensus RatingBuy# Analysts11Avg. Consensus PT$112Upside to Avg. PT-4.3%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 9, 2026	Barrington Research	Michael Petusky	PT Raise	Outperform	$118→$140
Oct 9, 2026	Mizuho	Anthony Petrone	PT Raise	Outperform	$95→$140
Oct 8, 2026	BTIG	Marie Thibault	PT Raise	Buy	$110→$130
Sep 17, 2026	Citigroup	Joanne Wuensch	Upgrade	Neutral→Buy	$92→$123
Sep 3, 2026	Raymond James	Andrew Cooper	PT Raise	Outperform	$105→$125
Aug 21, 2026	Baird	David Rescott	PT Raise	Outperform	$96→$119
Aug 19, 2026	Barrington Research	Michael Petusky	PT Raise	Outperform	$95→$118
Aug 18, 2026	BTIG	Marie Thibault	PT Raise	Buy	$96→$110
Aug 7, 2026	Citigroup	Joanne Wuensch	PT Raise	Neutral	$79→$92
Aug 7, 2026	JP Morgan	Allen Gong	PT Raise	Neutral	$62→$86
Aug 6, 2026	BTIG	Marie Thibault	PT Raise	Buy	$84→$96
Jul 15, 2026	Mizuho	Anthony Petrone	PT Raise	Outperform	$85→$90
Jun 26, 2026	BTIG	Marie Thibault	Maintained	Buy	$84
Jun 17, 2026	BTIG	Marie Thibault	Maintained	Buy	$84
Jun 15, 2026	Mizuho	Anthony Petrone	PT Raise	Outperform	$70→$85
May 28, 2026	Citigroup	Joanne Wuensch	PT Raise	Neutral	$64→$70
May 22, 2026	B of A Securities	Craig Bijou	Upgrade	Neutral→Buy	$72→$80
May 12, 2026	Barrington Research	Michael Petusky	PT Cut	Outperform	$94→$89
May 8, 2026	JP Morgan	Allen Gong	PT Cut	Neutral	$74→$62
Apr 13, 2026	Mizuho	Anthony Petrone	PT Cut	Outperform	$80→$70

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Barrington Research Maintains Outperform on Haemonetics, Raises Price Target to $140

Barrington Research analyst Michael Petusky maintains Haemonetics (NYSE:HAE) with a Outperform and raises the price target from $118 to $140.

Benzinga Newsdesk

PRO
Mizuho Maintains Outperform on Haemonetics, Raises Price Target to $140

Mizuho analyst Anthony Petrone maintains Haemonetics (NYSE:HAE) with a Outperform and raises the price target from $95 to $140.

Benzinga Newsdesk

PRO
BTIG Maintains Buy on Haemonetics, Raises Price Target to $130

BTIG analyst Marie Thibault maintains Haemonetics (NYSE:HAE) with a Buy and raises the price target from $110 to $130.

Benzinga Newsdesk

This JB Hunt Transport Analyst Turns Bullish; Here Are Top 4 Upgrades For Thursday

Analysts upgraded SUNB, HAWK, and more, revising ratings and price targets.

Avi Kapoor

PRO
Citigroup Upgrades Haemonetics to Buy, Raises Price Target to $123

Citigroup analyst Joanne Wuensch upgrades Haemonetics (NYSE:HAE) from Neutral to Buy and raises the price target from $92 to $123.

Benzinga Newsdesk

PRO
Raymond James Maintains Outperform on Haemonetics, Raises Price Target to $125

Raymond James analyst Andrew Cooper maintains Haemonetics (NYSE:HAE) with a Outperform and raises the price target from $105 to $125.

Benzinga Newsdesk

Haemonetics Corp

Haemonetics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Barrington Research Maintains Outperform on Haemonetics, Raises Price Target to $140

PRO
Mizuho Maintains Outperform on Haemonetics, Raises Price Target to $140

PRO
BTIG Maintains Buy on Haemonetics, Raises Price Target to $130

This JB Hunt Transport Analyst Turns Bullish; Here Are Top 4 Upgrades For Thursday

PRO
Citigroup Upgrades Haemonetics to Buy, Raises Price Target to $123

PRO
Raymond James Maintains Outperform on Haemonetics, Raises Price Target to $125

People Also Watch

People Also Watch

Haemonetics Corp

Haemonetics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROBarrington Research Maintains Outperform on Haemonetics, Raises Price Target to $140

PROMizuho Maintains Outperform on Haemonetics, Raises Price Target to $140

PROBTIG Maintains Buy on Haemonetics, Raises Price Target to $130

This JB Hunt Transport Analyst Turns Bullish; Here Are Top 4 Upgrades For Thursday

PROCitigroup Upgrades Haemonetics to Buy, Raises Price Target to $123

PRORaymond James Maintains Outperform on Haemonetics, Raises Price Target to $125

People Also Watch

People Also Watch

PRO
Barrington Research Maintains Outperform on Haemonetics, Raises Price Target to $140

PRO
Mizuho Maintains Outperform on Haemonetics, Raises Price Target to $140

PRO
BTIG Maintains Buy on Haemonetics, Raises Price Target to $130

PRO
Citigroup Upgrades Haemonetics to Buy, Raises Price Target to $123

PRO
Raymond James Maintains Outperform on Haemonetics, Raises Price Target to $125